drugset / Trial / NCT04994236

Hepatic Artery Infusion Chemotherapy for Unresectable Hepatocelluar Carcinoma Who Failed to Systemic Therapy

NCT04994236 ↗

Phase 2 Unknown 49 enrolled Hui-Chuan Sun
NaSingle-groupOpen-labelTreatment

Summary

There are limited treatment options for patients with unresectable hepatocellular carcinoma (HCC) who failed to the combination therapy with targeted agents plus anti-PD-1/PD-L1. Hepatic artery infusion chemotherapy (HAIC) had shown potent antitumor effects in single-centered studies when was used as first-line therapy. However, HAIC was not used as second or third-line therapy.

Timeline

Start
2021-07-01
Primary completion
2022-08-31
Completion
2022-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Leucovorin Small molecule 400 mg/m2 Other
Subject Oxaliplatin Small molecule 85 mg/m2 Other
Subject fluorouracil Small molecule 400 mg/m2 Other
Subject fluorouracil Small molecule 2400 mg/m2 Other